The global liquid biopsy market is anticipated to reach USD 6,014.2 million by 2025, growing at a CAGR of 33.4%. Increasing cancer prevalence is a prime factor driving the global liquid biopsy market. The current liquid biopsy market landscape is intricate with more than 50 corporations in the space steering the complete range of blood-based markers (e.g., ctDNA, CTCs, exosomes, miRNA, protein), technologies (e.g., dPCR, NGS), and application (e.g., early detection, diagnosis, treatment selection and disease monitoring), where liquid biopsies are utilized. The market is led by service providers with laboratory-developed test (e.g., Guardant Health, Foundation Medicine, Biocept,) consuming NGS-based pan-cancer methods.
Request a pdf sample @ https://www.adroitmarketresearch.com/contacts/request-sample/1413
The report covers the current status and future traits of the market at global as well as country level along with the depiction of the industry’s value chain. In addition, the study also assesses the market based on Porter’s five forces analysis. Noticeable players serving in the global liquid biopsy market have also been studied in detail. The global liquid biopsy market has been segmented based on applications, cancer type, and circulating biomarker types. Based on applications, the market is broken down into early cancer screening, therapy selection, treatment monitoring and risk of recurrence. Early cancer screening is expected to account nearly 50% market share by 2025.
Increasing incidences of chronic diseases among the population, growing geriatric population and rising sedentary lifestyle of people especially in urban regions are the major factors fueling the growth of global liquid biopsy market over the forecast timeframe. Cancer is one of the leading causes of deaths. Moreover, increasing cases of diseases such as cancer, tumor, cardiovascular illnesses and others are contributing to the increasing requirement of liquid biopsy in hospitals, fueling its industry growth in coming years. Also, shifts in dietary habits of the individuals as well as increasing preference for fast food and ready to eat food products due to lack of time and fast lifestyle of the people are also propelling the market growth over the forecast timeframe.
Access the full report with Table of Contents and List of Figures @ https://www.adroitmarketresearch.com/industry-reports/liquid-biopsy-market
Also, advantages of liquid biopsy such as early prognosis, reduced cost, detection of tumor heterogeneity, therapy monitoring, acquired drug resistance, and patient comfort (by eliminating the need for surgery) as compared to the traditional techniques of cancer diagnosis are also fueling the demand for the procedure, creating opportunities for the growth of global liquid biopsy market in coming years. Further, rising importance of early diagnosis of diseases for the ease of treatment caused because of it is further fueling the growth of global liquid biopsy industry through analysis timeframe.
Moreover, increasing adoption of new technologies over the past few years, integration of advanced procedures in the healthcare industry as well as rising expenditure of the healthcare sector especially for research and development activities across the globe is fueling the growth of global liquid biopsy industry over the analysis timeframe. However, lack of sensitivity and specificity of the procedure as well as inaccurate behavior of the biopsy procedure increases the implementation of tissue biopsy among the doctors, which is likely to hamper the growth of global liquid biopsy market in coming years.
Asia Pacific is anticipated to be the fastest growing market through the forecast period. In this region rising income, increased urbanization, growing cancer cases, and government’s focus on healthcare facilities is driving the liquid biopsy market. However, there are substantial barriers to liquid biopsy adoption. A number of assays intended on high-cost next generation sequencing technology are not reimbursed, obstructing market uptake. Moreover, cost of the procedure is facilitating access to a larger population in India, Japan and China, which depend heavily on out-of-pocket expenditure. Worldwide, in the race of active clinical trials in liquid biopsy East Asia ranks second, while China bangs the maximum number of trials. Therefore, it is advised that companies must design and develop randomized controlled trials and inclusion in guidelines to encourage broader acceptance and favorable payer coverage in Asia Pacific.
Place a direct purchase order @ https://www.adroitmarketresearch.com/researchreport/purchase/1413
Major players operating in the global liquid biopsy market are Biocept, Inc., Qiagen N.V., Roche Diagnostics, Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., Menarini-Silicon Biosystems, Trovagene, Inc., Guardant Health, Inc. and Genomic Health, Inc. among others.
Key segments of the global liquid biopsy market
Application Overview, 2017-2025 (USD Million)
Early cancer screening
Therapy selection
Treatment monitoring
Risk of recurrence
Cancer Type Overview, 2017-2025 (USD Million)
Lung cancer
Breast cancer
Colorectal cancer
Prostate cancer
Other cancers
Circulating Biomarker Overview, 2017-2025 (USD Million)
Circulating tumor cells (CTCs)
Circulating tumor DNA (ctDNA)
Other circulating biomarkers
Regional Overview, 2017-2025 (USD Million)
North America
US
Canada
Europe
Germany
United Kingdom
France
Rest of Europe
Asia Pacific
China
Japan
India
Rest of Asia Pacific
Rest of the World
Enquire for in-depth information before buying this report @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1413
Major points from Table of Contents:
- Introduction
- Research Methodology
- Market Outlook
- Liquid Biopsy Market by Application, 2017-2025 (USD Million)
- Liquid Biopsy Market by Cancer Type, 2017-2025 (USD Million)
- Liquid Biopsy Market by Circulating Biomarker, 2017-2025 (USD Million)
- Liquid Biopsy Market by Region 2017-2025 (USD Million)
- Competitive Landscape
- Company Profiles
- Appendix
About Us:
Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a market’s size, key trends, participants and future outlook of an industry. We intend to become our clients’ knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code– Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.
Contact Us :
Ryan Johnson
Account Manager Global
3131 McKinney Ave Ste 600, Dallas,
TX 75204, U.S.A
Phone No.: USA: +1 972-362 -8199 / +91 9665341414
